Warning: session_start(): open(/home/tayedi/public_html/src/var/sessions/sess_b209f8c0ef820cdd2f84b51a9494d070, O_RDWR) failed: No space left on device (28) in /home/tayedi/public_html/src/bootstrap.php on line 59

Warning: session_start(): Failed to read session data: files (path: /home/tayedi/public_html/src/var/sessions) in /home/tayedi/public_html/src/bootstrap.php on line 59
Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease - Tayedi Search engine

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

5 months ago 249

Novo Nordisk, the Danish drugmaker behind Ozempic and other weight-loss drugs, said it’s paying up to $5.2 billion to buy Akero Therapeutics, a biotech with a drug in a late-stage trial to treat a fatal liver disease.

Read Entire Article

Novo Nordisk is paying up to $5.2 billion for a San Francisco biotech working on liver disease

Related

Here are 7 charts guaranteed to stress you out about the sto...

More companies than usual are beating Wall Street’s expectat...

These ‘safer’ chip stocks have boomed this year. Is it too l...

Trending

Popular

More companies than usual are beating Wall Street’s expectat...

Binance teams up with Franklin Templeton to use tokenized mo...

ETH open interest falls to 3-year low: What does it mean for...

Here are 7 charts guaranteed to stress you out about the sto...

Memory-chip stocks are still quite cheap — especially if you...

These ‘safer’ chip stocks have boomed this year. Is it too l...

UK government appoints HSBC for tokenized bond pilot

All social program benefits can be distributed onchain: Comp...

Sharplink's Lubin and Chalom make their case for ether DATs ...

Ethereum developers suggest using ZK tech to anonymize AI us...